Status: current, Sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jul 2018. Module: SNOMED CT core
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 3693212013 | Erythromycin 40 mg/mL and zinc acetate 12 mg/mL cutaneous solution | en | Synonym (core metadata concept) | Active | Only initial character case insensitive (core metadata concept) | SNOMED CT core |
| 3693213015 | Product containing precisely erythromycin 40 milligram/1 milliliter and zinc acetate 12 milligram/1 milliliter conventional release cutaneous solution (clinical drug) | en | Fully specified name | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 3958251000005112 | erytromycin + zinkacetat 40 mg/12 mg/ml opløsning til topikal anvendelse | da | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | dansk modul |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Erythromycin 40 mg/mL and zinc acetate 12 mg/mL cutaneous solution | Is a | erythromycin til topikal anvendelse | false | Inferred relationship | Some | ||
| Erythromycin 40 mg/mL and zinc acetate 12 mg/mL cutaneous solution | Has active ingredient | Erythromycin (substance) | false | Inferred relationship | Some | ||
| Erythromycin 40 mg/mL and zinc acetate 12 mg/mL cutaneous solution | Is a | Product containing erythromycin and zinc acetate (medicinal product) | false | Inferred relationship | Some | ||
| Erythromycin 40 mg/mL and zinc acetate 12 mg/mL cutaneous solution | Has active ingredient | Zinc acetate (substance) | false | Inferred relationship | Some | ||
| Erythromycin 40 mg/mL and zinc acetate 12 mg/mL cutaneous solution | Has active ingredient | Zinc | false | Inferred relationship | Some | ||
| Erythromycin 40 mg/mL and zinc acetate 12 mg/mL cutaneous solution | Has active ingredient | Baktericid | false | Inferred relationship | Some | ||
| Erythromycin 40 mg/mL and zinc acetate 12 mg/mL cutaneous solution | Has manufactured dose form | kutan OG/ELLER transdermal doseringsform | false | Inferred relationship | Some | ||
| Erythromycin 40 mg/mL and zinc acetate 12 mg/mL cutaneous solution | Has manufactured dose form | lægemiddelopløsning | false | Inferred relationship | Some | ||
| Erythromycin 40 mg/mL and zinc acetate 12 mg/mL cutaneous solution | Has manufactured dose form | Cutaneous solution | true | Inferred relationship | Some | ||
| Erythromycin 40 mg/mL and zinc acetate 12 mg/mL cutaneous solution | Is a | Product containing zinc acetate in topical dosage form | false | Inferred relationship | Some | ||
| Erythromycin 40 mg/mL and zinc acetate 12 mg/mL cutaneous solution | Has concentration strength denominator value | en | false | Inferred relationship | Some | 2 | |
| Erythromycin 40 mg/mL and zinc acetate 12 mg/mL cutaneous solution | Has concentration strength denominator value | en | false | Inferred relationship | Some | 1 | |
| Erythromycin 40 mg/mL and zinc acetate 12 mg/mL cutaneous solution | Has concentration strength numerator unit | mg | true | Inferred relationship | Some | 1 | |
| Erythromycin 40 mg/mL and zinc acetate 12 mg/mL cutaneous solution | Has concentration strength denominator unit | mL | true | Inferred relationship | Some | 1 | |
| Erythromycin 40 mg/mL and zinc acetate 12 mg/mL cutaneous solution | Count of base of active ingredient | to | false | Inferred relationship | Some | ||
| Erythromycin 40 mg/mL and zinc acetate 12 mg/mL cutaneous solution | Has concentration strength denominator unit | mL | true | Inferred relationship | Some | 2 | |
| Erythromycin 40 mg/mL and zinc acetate 12 mg/mL cutaneous solution | Has concentration strength numerator unit | mg | true | Inferred relationship | Some | 2 | |
| Erythromycin 40 mg/mL and zinc acetate 12 mg/mL cutaneous solution | Has basis of strength substance (attribute) | Erythromycin (substance) | false | Inferred relationship | Some | 2 | |
| Erythromycin 40 mg/mL and zinc acetate 12 mg/mL cutaneous solution | Has precise active ingredient | Zinc acetate (substance) | false | Inferred relationship | Some | 1 | |
| Erythromycin 40 mg/mL and zinc acetate 12 mg/mL cutaneous solution | Has concentration strength numerator value | 12 | false | Inferred relationship | Some | 1 | |
| Erythromycin 40 mg/mL and zinc acetate 12 mg/mL cutaneous solution | Has basis of strength substance (attribute) | Zinc acetate (substance) | false | Inferred relationship | Some | 1 | |
| Erythromycin 40 mg/mL and zinc acetate 12 mg/mL cutaneous solution | Has precise active ingredient | Erythromycin (substance) | false | Inferred relationship | Some | 2 | |
| Erythromycin 40 mg/mL and zinc acetate 12 mg/mL cutaneous solution | Has concentration strength numerator value | 40 | false | Inferred relationship | Some | 2 | |
| Erythromycin 40 mg/mL and zinc acetate 12 mg/mL cutaneous solution | Is a | Erythromycin and zinc acetate only product in cutaneous dose form | true | Inferred relationship | Some | ||
| Erythromycin 40 mg/mL and zinc acetate 12 mg/mL cutaneous solution | Plays role | Antibacterial therapeutic role (role) | true | Inferred relationship | Some | ||
| Erythromycin 40 mg/mL and zinc acetate 12 mg/mL cutaneous solution | Has basis of strength substance (attribute) | Erythromycin (substance) | true | Inferred relationship | Some | 1 | |
| Erythromycin 40 mg/mL and zinc acetate 12 mg/mL cutaneous solution | Has precise active ingredient | Erythromycin (substance) | true | Inferred relationship | Some | 1 | |
| Erythromycin 40 mg/mL and zinc acetate 12 mg/mL cutaneous solution | Has basis of strength substance (attribute) | Zinc acetate (substance) | true | Inferred relationship | Some | 2 | |
| Erythromycin 40 mg/mL and zinc acetate 12 mg/mL cutaneous solution | Has precise active ingredient | Zinc acetate (substance) | true | Inferred relationship | Some | 2 |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
Reference Sets
Description inactivation indicator reference set
FHIR